Q-omics provides the consensus-scored CSGALNACT1 profile across patient tissues and cancer cell-line models. CSGALNACT1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CSGALNACT1 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, CSGALNACT1 RNA expression shows 18,958 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and THCA as cancer lineages where CSGALNACT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSGALNACT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSGALNACT1 survival associations across molecular data types. CSGALNACT1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSGALNACT1 RNA expression–survival associations across cancer types. High CSGALNACT1 expression shows unfavorable associations in KIRP and LUAD, but favorable associations in HNSC, ACC, SKCM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CSGALNACT1 RNA expression.
This table summarizes CSGALNACT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CSGALNACT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSGALNACT1 shows lower tumor expression in THCA, BLCA, UCEC, LUSC and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher CSGALNACT1 RNA expression in normal versus tumor tissue (log2 FC = −3.199, t-test p < 0.001).
This table shows molecular features associated with CSGALNACT1 in patient tissues and cancer cell lines. In patient samples, CSGALNACT1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CSGALNACT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
